STGAT-MAD: Spatial-Temporal Graph Attention Network for Multivariate Time Series Anomaly Detection

Anomaly detection in multivariate time series data is challenging due to complex temporal and feature correlations and heterogeneity. This paper proposes a novel unsupervised multi-scale stacked spatial-temporal graph attention network for multivariate time series anomaly detection (STGATMAD). The core of our framework is to coherently capture the feature and temporal correlations among multivariate time-series data with stackable STGAT networks. Meanwhile, a multi-scale input network is exploited to capture the temporal correlations in different time-scales. Experiments on a new wind turbine dataset (built and released by us) and three public datasets show that our method detects anomalies more accurately than baseline approaches and provide interpretability through observing the attention score among multiple sensors and different times

Residual Gas Adsorption and Desorption in the Field Emission of Titanium-Coated Carbon Nanotubes

Titanium (Ti)-coated multiwall carbon nanotubes (CNTs) emitters based on the magnetronsputtering process are demonstrated, and the influences of modification to CNTs on the residual gasadsorption, gas desorption, and their field emission characteristic are discussed. Experimental resultsshow that Ti nanoparticles are easily adsorbed on the surface of CNTs due to the “defects” producedby Ar+irradiation pretreatment. X-ray photoelectron spectroscopy (XPS) characterization showedthat Ti nanoparticles contribute to the adsorption of ambient molecules by changing the chemicalbonding between C, Ti, and O. Field emission of CNTs coated with Ti nanoparticles agree well withthe Fowler–Nordheim theory. The deviation of emission current under constant voltage is 6.3% and8.6% for Ti-CNTs and pristine CNTs, respectively. The mass spectrometry analysis illustrated thatTi-coated CNTs have a better adsorption capacity at room temperature, as well as a lower outgassingeffect than pristine CNTs after degassing in the process of field emission

Prediction of overall survival for patients with metastatic castration-resistant prostate cancer : development of a prognostic model through a crowdsourced challenge with open clinical trial data

Background Improvements to prognostic models in metastatic castration-resistant prostate cancer have the potential to augment clinical trial design and guide treatment strategies. In partnership with Project Data Sphere, a not-for-profit initiative allowing data from cancer clinical trials to be shared broadly with researchers, we designed an open-data, crowdsourced, DREAM (Dialogue for Reverse Engineering Assessments and Methods) challenge to not only identify a better prognostic model for prediction of survival in patients with metastatic castration-resistant prostate cancer but also engage a community of international data scientists to study this disease. Methods Data from the comparator arms of four phase 3 clinical trials in first-line metastatic castration-resistant prostate cancer were obtained from Project Data Sphere, comprising 476 patients treated with docetaxel and prednisone from the ASCENT2 trial, 526 patients treated with docetaxel, prednisone, and placebo in the MAINSAIL trial, 598 patients treated with docetaxel, prednisone or prednisolone, and placebo in the VENICE trial, and 470 patients treated with docetaxel and placebo in the ENTHUSE 33 trial. Datasets consisting of more than 150 clinical variables were curated centrally, including demographics, laboratory values, medical history, lesion sites, and previous treatments. Data from ASCENT2, MAINSAIL, and VENICE were released publicly to be used as training data to predict the outcome of interest-namely, overall survival. Clinical data were also released for ENTHUSE 33, but data for outcome variables (overall survival and event status) were hidden from the challenge participants so that ENTHUSE 33 could be used for independent validation. Methods were evaluated using the integrated time-dependent area under the curve (iAUC). The reference model, based on eight clinical variables and a penalised Cox proportional-hazards model, was used to compare method performance. Further validation was done using data from a fifth trial-ENTHUSE M1-in which 266 patients with metastatic castration-resistant prostate cancer were treated with placebo alone. Findings 50 independent methods were developed to predict overall survival and were evaluated through the DREAM challenge. The top performer was based on an ensemble of penalised Cox regression models (ePCR), which uniquely identified predictive interaction effects with immune biomarkers and markers of hepatic and renal function. Overall, ePCR outperformed all other methods (iAUC 0.791; Bayes factor >5) and surpassed the reference model (iAUC 0.743; Bayes factor >20). Both the ePCR model and reference models stratified patients in the ENTHUSE 33 trial into high-risk and low-risk groups with significantly different overall survival (ePCR: hazard ratio 3.32, 95% CI 2.39-4.62, p Interpretation Novel prognostic factors were delineated, and the assessment of 50 methods developed by independent international teams establishes a benchmark for development of methods in the future. The results of this effort show that data-sharing, when combined with a crowdsourced challenge, is a robust and powerful framework to develop new prognostic models in advanced prostate cancer.Peer reviewe

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67-0.95]; P=0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49-0.94]) and secondary (HR, 0.85 [95% CI, 0.69-1.06]) prevention groups (P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61-1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59-1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56-1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups (P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years

Applications of Vacuum Measurement Technology in China’s Space Programs

The significance of vacuum measurement technology is increasingly prominent in China’s thriving space industry. Lanzhou Institute of Physics (LIP) has been dedicated to the development of payloads and space-related vacuum technology for decades, and widely participated in China’s space programs. In this paper, we present several payloads carried on satellites, spaceships, and space stations; the methodologies of which covered the fields of total and partial pressure measurement, vacuum and pressure leak detection, and standard gas inlet technology. Then, we introduce the corresponding calibration standards developed in LIP, which guaranteed the detection precision of these payloads. This review also provides some suggestions and expectations for the future development and application of vacuum measurement technology in space exploration

Super-Resolution and Wide-Field-of-View Imaging Based on Large-Angle Deflection with Risley Prisms

A novel single camera combined with Risley prisms is proposed to achieve a super-resolution (SR) imaging and field-of-view extension (FOV) imaging method. We develop a mathematical model to consider the imaging aberrations caused by large-angle beam deflection and propose an SR reconstruction scheme that uses a beam backtracking method for image correction combined with a sub-pixel shift alignment technique. For the FOV extension, we provide a new scheme for the scanning position path of the Risley prisms and the number of image acquisitions, which improves the acquisition efficiency and reduces the complexity of image stitching. Simulation results show that the method can increase the image resolution to the diffraction limit of the optical system for imaging systems where the resolution is limited by the pixel size. Experimental results and analytical verification yield that the resolution of the image can be improved by a factor of 2.5, and the FOV extended by a factor of 3 at a reconstruction factor of 5. The FOV extension is in general agreement with the simulation results. Risley prisms can provide a more general, low-cost, and efficient method for SR reconstruction, FOV expansion, central concave imaging, and various scanning imaging

Super-Resolution and Wide-Field-of-View Imaging Based on Large-Angle Deflection with Risley Prisms

A novel single camera combined with Risley prisms is proposed to achieve a super-resolution (SR) imaging and field-of-view extension (FOV) imaging method. We develop a mathematical model to consider the imaging aberrations caused by large-angle beam deflection and propose an SR reconstruction scheme that uses a beam backtracking method for image correction combined with a sub-pixel shift alignment technique. For the FOV extension, we provide a new scheme for the scanning position path of the Risley prisms and the number of image acquisitions, which improves the acquisition efficiency and reduces the complexity of image stitching. Simulation results show that the method can increase the image resolution to the diffraction limit of the optical system for imaging systems where the resolution is limited by the pixel size. Experimental results and analytical verification yield that the resolution of the image can be improved by a factor of 2.5, and the FOV extended by a factor of 3 at a reconstruction factor of 5. The FOV extension is in general agreement with the simulation results. Risley prisms can provide a more general, low-cost, and efficient method for SR reconstruction, FOV expansion, central concave imaging, and various scanning imaging